HIBROW HLTHCARE
GenericsHIBROW HLTHCARE is a generic drug manufacturer focused on Neurology, Metabolic, Cardiovascular.
HIBROW HLTHCARE's Key Drugs
HIBROW HLTHCARE's core commercial portfolio centers on BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, spanning Neurology and Metabolic — its most strategically important drugs approved in the last 15 years.
HIBROW HLTHCARE's Recent FDA Approvals
New NDA/BLA approvals for HIBROW HLTHCARE over the last two years — novel drugs only, excluding generics and label supplements.
HIBROW HLTHCARE's Therapeutic Areas
HIBROW HLTHCARE's approved drugs and pipeline span 4 therapeutic areas, led by Neurology and Metabolic, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HIBROW HLTHCARE's Top Competitors
HIBROW HLTHCARE's closest competitors by therapeutic-area and drug-target overlap include Roche, B BRAUN, and Novo Nordisk. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HIBROW HLTHCARE Pipeline Snapshot
Active clinical trials for HIBROW HLTHCARE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2016-11-23
- Latest
- 2026-06-18
- Applications
- 20